Dr. Grupp on Optimal Treatment Settings for CAR-Modified T Cells

Video

Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia.

Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia (ALL).

CAR-modified T cell therapies have generated excitement, as novel treatments for patients with ALL. In updated findings from 39 pediatric patients with relapsed/refractory ALL, the complete remission rate was 92%. In this population, this is a good treatment option, Grupp notes.

Given the high-level of efficacy seen with upfront chemotherapy in pediatric patients, Grupp believes the CAR T cell therapies are best suited for later lines of treatment. However, in adult patients with ALL, approximately half of patients progress on frontline therapy. For this population, CAR T cell therapies could be beneficial in earlier settings. At this point, Grupp remains uncertain whether the novel immunotherapies could ever replace frontline chemotherapy in ALL.

<<<

View more from the 2014 ASH Annual Meeting

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.